+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia



Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia



Intervirology 50(5): 361-368



To evaluate power of amino acid polymorphisms in core protein of hepatitis C virus (HCV) for predicting sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin, when they were combined with virological response. Peg-IFN/ribavirin was given to 118 patients infected with HCV genotype 1b in high viral loads. Amino acid polymorphisms (Arg70 vs. Gln70 and Leu91 vs. Met91) in combination with on-treatment virological responses were correlated with SVR. End-of-treatment response (ETR) was achieved in 71% and SVR in 47% of the 118 patients. In multivariate analysis, Arg70 and Leu91, and higher ribavirin dose were independently associated with ETR. In patients with Gln70 and/or Met91, SVR was more frequent in those with than without prompt virological response (PVR) for a decrease in viral load >or=1.0 log by 48 h. Specificity in predicting patients without ETR and SVR, in combination with core polymorphisms, was not different between PVR and early virological response at 12 weeks. Core polymorphisms combined with PVR would be useful in promptly identifying the patients who will not respond to Peg-IFN/ribavirin, thereby avoiding unrewarding side effects and high costs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 019772433

Download citation: RISBibTeXText

PMID: 17728547

DOI: 10.1159/000107707


Related references

Viral dynamics and prediction of response to treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C. Revista Espanola de Enfermedades Digestivas 101(10): 665-670, 2009

Viral kinetics and early prediction of non-response to pegylated interferon/ribavirin in HIV infected patients with genotypes 1/4-related chronic hepatitis C. Hepatology 38(4 Suppl 1): 749A, 2003

Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy. Intervirology 55(1): 1-11, 2012

Viral kinetics and early prediction of non response to pegylated interferon/ribavirin in HCV genotypes 1/4 according to HIV serostatus. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 43: 495, 2003

Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks. Hepatology Research 44(2): 179-186, 2014

Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C. Gut and Liver 8(4): 421-427, 2014

Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection. Hepatology 56(5): 1611-1621, 2012

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. Journal of Hepatology 54(3): 439-448, 2011

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load. Journal of Gastroenterology 47(10): 1143-1151, 2012

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load. Digestive Diseases 31(5-6): 426-433, 2013

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Journal of Gastroenterology and Hepatology 28(3): 443-449, 2013

S1005 Very Early Viral Response to Treatment of Hepatitis C Virus (Hcv) with Pegylated Interferon and Ribavirin: the First 24 Hours. Gastroenterology 134(4): A-773, 2008

Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin. Journal of Hepatology 55(5): 989-995, 2011

Prediction of early virologic response to treatment with 40kD pegylated -interferon alfa2a/ribavirin in patients with chronic hepatitis C. Gastroenterology 122(4 Suppl 1): A 626, 2002

Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy. Journal of Medical Virology 86(2): 224-234, 2014